COVID-19 publications - Week

(1)

Update February 8 - February 14, 2021, Dr. Peter J. Lansberg MD, PhD

Weekly COVID-19 Literature Update

will keep you up-to-date with all recent PubMed publications categorized by relevant topics

COVID-19 publications - Week 06 2021

1165 Publications

PubMed based Covid-19 weekly literature update

For those interested in receiving weekly updates

click here

For questions and requests for topics to add send an e-mail [email protected]

Reliable on-line resources for Covid 19

WHO Daily dashbord Country Guidance Travel restriction Covid Counter Covid forcasts CDC AHA ESC EMEA Evidence EPPI Wikipedia Cochrane BMJ The Lancet

New England Journal of Medicine JAMA

Cell Science

Oxford Universtiy Press Cambridge Univeristy Press Springer Nature

Elsevier Wiley

(2)

Cardionerds - COVID-19 Genomic epidemiology Oxygenation Ventilation toolkit German (ICU) bed capacity COVID-19 Projections tracker AAN - Neurology resources COVID-19 resources (Harvard) COVID-19 resources (McMasters) COVID-19 resources (NHLBI) COVID-19 resources (MEDSCAPE) COVID-19 Diabetes (JDRF) COVID-19 TELEMEDICINE (BMJ) Global Causes of death (Johns Hopkins) COVID-19 calculators (Medscap)

PLOS

LitCovid NIH-NLM SSRN (Pre-prints)

COVID reference (Steinhauser Verlag) Retracted papers

COVID-19 risk tools - Apps Web app for SARS-CoV2 mutations

Guidelines

NICE Guidelines Covid-19

Korean CDC Covid-19 guidelines Flattening the curve - Korea IDSA COVID-19 Guidelines

Airway Management Clinical Practice Guidelines (SIAARTI/EAMS, 2020) ESICM Ventilation Guidelines

Performing Procedures on Patients With Known or Suspected COVID-19 (ASA, 2020) OSHA Guidance on Preparing the Workplace for COVID-19 (2020)

Policy for Sterilizers, Disinfectant Devices, and Air Puriﬁers (FDA, 2020) Breast Cancer Patient Triage Guidelines (CPBCC, 2020)

clinical guidance for adult Belgian patients with suspected or conﬁrmed COVID-19 National Covid-19 Testing Action Plan (Rockefeller Foundation)

ASE issues Echo-cardiography guidance

Trials & Registries

CAPACITY European registry COVID 19 patients WHO launches global megatrial

FDA launches Convalescent plasma trial

Lets Beat Covid-19 Survey to help plan hospital services COVID IBD registry

Google mobility reports per country COVID 19

World's largest trial of potential coronavirus treatments rolled out across the UK Pregnancy Registry (US)

ICNARC report on COVID-19 in critical care - NHS April 24 COVID-19 Human Genetics - Biobanks

(3)

COVID19 settings of transmission database COVID-19 prevention network

Covid-Plex trial - (plasma exchange & convalescent plasma trial)

The Covid-Plex trial is an investigator initiated, multicenter, parallel-group, open-label randomized clinical trial aiming to randomize patients with severe COVID-19 to standard care or standard care plus plasmapheresis and convalescent plasma.

If you are interested to participate Please contact Wladimir Szpirt, Nicholas Carlson Anders, or Perner Bo Feldt-Rasmussen. Depts. Of Intensive Care Therapy and

Nephrology, Copenhagen University Hospital Rigshospitalet, Denmark

Covid-Plex trial

Mainstream Media

New York Times - Corona update

My Patients Need Me. Can I Quit?

C.D.C. Announces $200 Million ‘Down Payment’ to Track Virus Variants Europe’s Pandemic Debt Is Dizzying. Who Will Pay?

Coronavirus Vaccine Nears Final Tests in Cuba. Tourists May Be Inoculated. To Get Their Lives Back, Teens Volunteer for Vaccine Trials

Potential for New Coronaviruses May Be Greater Than Known Opera Singers Help Covid-19 Patients Learn to Breathe Again

Covid-Linked Syndrome in Children Is Growing, and Cases Are More Severe Coronavirus Vaccine Tracker

Coronavirus Drug and Treatment Tracker

Washington Post - Corona update

Pandemic cut U.S. life expectancy by a year during the first half of 2020

Pfizer and Moderna vaccines have reduced effectiveness against S. African variant U.K. gets approval to infect healthy volunteers in first coronavirus ‘challenge trial’ Covid-19 could have a long-term impact on the brain. We need more research. A vaccine entrepreneur held an indoor conference. Now dozens have the virus. Which vaccine should you get? Whichever one you can.

Number of Israelis reinfected by South African variant rises to 3, raising concerns Four reasons experts say coronavirus cases are dropping in the United States Oxford-AstraZeneca begins a vaccine trial for children. Youngest group to be tested.

(4)

Brazil health workers accused of giving Covid vaccinations with empty syringes Mass testing still a vital tool in Covid efforts despite UK vaccine success Dutch court reinstates Covid curfew minutes before its start time

‘Encouraging’ signs for Covid vaccine as over-80s deaths fall in England Contact tracing alone has little impact on curbing Covid spread, report finds

Key Articles

Ky Articles

Post-COVID-19 Symptom Burden: What is Long-COVID and How Should We Manage It? Lung 2021:1-7Sykes DL, Holdsworth L, Jawad N et al.

http://www.ncbi.nlm.nih.gov/pubmed/?term=33569660

Patients infected with the SARS-CoV2 virus can experience symptoms that outlast the acute phase of the COVID-19 disease. These lasting symptoms are referred to as Long-Covid and defined as a protracted course of various physical and

neuropsychiatric symptoms that persist for more than 12 weeks without an alternative explanation. This review discusser relevant clinical features, management, and causes. Biopsychosocial effects are suggested as a more prominent explanation than long-term viral damage to vital organs and CNS.

Corona in Children: the Co-Ki Study: Relevance of SARS-CoV-2 in outpatient pediatric services in Germany. Monatsschr. Kinderheilkd. 2021; 169:39-45Schwarz

S, Jenetzky E, Krafft H et al.

The German CoKi study is a pediatrician-based registry to explore the relevant features of COVID-19 infections in children. Out of the 670 000 children that were managed by 557 pediatricians, 7707 children were tested using the standard PCR test. Only 198 had a positive test result (2.6%). Antibodies were present in 82 cases (11.2%). Based on the findings in this registry, the authors concluded that in children both the risk of complications and the risk of infecting adults was extremely small. Only one case was discovered but deemed unlikely after a telephone follow-up.

The use of therapeutic plasma exchange as adjunctive therapy in the treatment of coronavirus disease 2019: A critical appraisal of the current evidence. J.

Clin. Apher. 2021; Lu W, Kelley W, Fang DC et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=33578448

Alternatives to vaccines are urgently needed to adequately manage COVID-19 patients experiencing serious complications. Repurposing existing drugs,

experimental new treatments, and therapeutic plasma exchange (TPE) are explored in numerous clinical trials. This review critically evaluates the role of TPE for COVID-19. Potential mechanisms, evidence of TPE benefits in a broad spectrum of other diseases, and data collected in observational studies and registries are summarized in this comprehensive review. Currently, the potential benefit of TPE lacks proper evidence to formulate reliable recommendations. To bridge this gap in our knowledge, the LEOSS (Lean European Open Survey on SARS-CoV-2 Infected

(5)

Patients) registry, an international registry covering all aspects of TPE, was initiated. Additionally, Of the 3000 trials registered at clinicaltrials.gov, 10 evaluate the benefits of TPE.

Hydrating the Respiratory Tract: An Alternative Explanation Why Masks Lower Severity of COVID-19. Biophys. J. 2021; Courtney JM, Bax A.

Differences in Immune Responses between Children and Adults with COVID-19. Curr Med Sci 2021; 41:58-61Yuan Y, Wang QP, Sun D et al.

Hepatotropic Properties of SARS-CoV-2-Preliminary Results of Cross-Sectional Observational Study from the First Wave COVID-19 Pandemic. J Clin Med 2021;

10Wiśniewska H, Skonieczna-Żydecka K, Parczewski M et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=33572429

Is SARS-CoV-2 Transmitted Through Breastfeeding? Indian J Pediatr 2021;

Thanigainathan S, Kaliyaperumal V, Sivanandan S et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=33555566

Viral Infection and Cardiovascular Disease: Implications for the Molecular Basis of COVID-19 Pathogenesis. Int J Mol Sci 2021; 22Seeherman S, Suzuki YJ.

Current treatment in COVID-19 disease: a rapid review. Drugs Context 2021;

10Rodriguez-Guerra M, Jadhav P, Vittorio TJ. http://www.ncbi.nlm.nih.gov/pubmed/? term=33569082

The EU one-stop-shop collection of publicly available information on COVID-19 in vitro diagnostic medical devices. F1000Res 2020; 9:1296Petrillo M, Querci M,

Tkachenko O et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=33564397

The impact of the COVID-19 pandemic on maternal mortality in Brazil: 523 maternal deaths by acute respiratory distress syndrome potentially associated with SARS-CoV-2. Int J Gynaecol Obstet 2021; Nakamura-Pereira M, Knobel R, de

Oliveira Menezes M et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=33570755

Consistency of recommendations and methodological quality of guidelines for the diagnosis and treatment of COVID-19. J Evid Based Med 2021; Luo X, Liu Y,

Ren M et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=33565225

Vigilance on New-Onset Atherosclerosis Following SARS-CoV-2 Infection. Front

Med (Lausanne) 2020; 7:629413Liu Y, Zhang HG. http://www.ncbi.nlm.nih.gov/pubmed/?term=33553222

(6)

Autopsy and statistical evidence of disturbed hemostasis progress in COVID-19: medical records from 407 patients. Thromb J 2021; COVID-19:8Jiang T, Lv B, Liu H et

al. http://www.ncbi.nlm.nih.gov/pubmed/?term=33568153

The Human Genome Organisation (HUGO) and the 2020 COVID-19 pandemic.

Hum Genomics 2021; 15:12Capps B, Joly Y, Mulvihill J, Lee WB. http://www.ncbi.nlm.nih.gov/pubmed/?term=33568209

Basic Science (70 articles)

1. Chemical composition and pharmacological mechanism of

ephedra-glycyrrhiza drug pair against coronavirus disease 2019 (COVID-19). Aging

(Albany NY) 2021; 13Li X, Qiu Q, Li M et al. http://www.ncbi.nlm.nih.gov/pubmed/? term=33581688

2. COVID-19: molecular pathophysiology, genetic evolution and prospective

therapeutics-a review. Arch. Microbiol. 2021; Raj CTD, Kandaswamy DK, Danduga

R et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=33555378

3. Age-dependent effects of the recombinant spike protein/SARS-CoV-2 on the

M-CSF- and IL-34-differentiated macrophages in vitro. Biochem. Biophys. Res.

Commun. 2021; 546:97-102Duarte C, Akkaoui J, Ho A et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=33578295

4. Induced dysregulation of ACE2 by SARS-CoV-2 plays a key role in COVID-19

severity. Biomed. Pharmacother. 2021; 137:111363Mehrabadi ME, Hemmati R,

Tashakor A et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=33582450 5. In Silico Screening of Natural Products Isolated from Mexican Herbal

Medicines against COVID-19. Biomolecules 2021; 11Rivero-Segura NA,

Gomez-Verjan JC. http://www.ncbi.nlm.nih.gov/pubmed/?term=33557097

6. Integrated network analysis reveals new genes suggesting COVID-19 chronic

effects and treatment. Brief. Bioinform. 2021; Pavel A, Del Giudice G, Federico A

et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=33569598

7. A proposed insight into the anti-viral potential of metallic nanoparticles

against novel coronavirus disease-19 (COVID-19). Bull Natl Res Cent 2021;

45:36Ibrahim Fouad G. http://www.ncbi.nlm.nih.gov/pubmed/?term=33564223 8. Deep Learning Algorithm Trained with COVID-19 Pneumonia Also Identiﬁes

Immune Checkpoint Inhibitor Therapy-Related Pneumonitis. Cancers (Basel)

2021; 13Mallio CA, Napolitano A, Castiello G et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=33562011

9. SARS-CoV-2 ORF9b inhibits RIG-I-MAVS antiviral signaling by interrupting

K63-linked ubiquitination of NEMO. Cell Rep. 2021:108761Wu J, Shi Y, Pan X et

10. Biologic Drugs for Rheumatoid Arthritis in the Context of Biosimilars,

(7)

Roszkowski L, Massalska M et al. http://www.ncbi.nlm.nih.gov/pubmed/? term=33557301

11. A Transcription Regulatory Sequence in the 5' Untranslated Region of

SARS-CoV-2 Is Vital for Virus Replication with an Altered Evolutionary Pattern against Human Inhibitory MicroRNAs. Cells 2021; 10Mohammadi-Dehcheshmeh

M, Moghbeli SM, Rahimirad S et al. http://www.ncbi.nlm.nih.gov/pubmed/? term=33557205

12. The vasoactive peptide MR-pro-adrenomedullin in COVID-19 patients: an

observational study. Clin Chem Lab Med 2021; Gregoriano C, Koch D, Kutz A et

13. Role of the SphK-S1P-S1PRs pathway in invasion of the nervous system by

SARS-CoV-2 Infection. Clin. Exp. Pharmacol. Physiol. 2021; Pan Y, Gao F, Zhao S

14. Deep Learning-Based Potential Ligand Prediction Framework for COVID-19

with Drug-Target Interaction Model. Cognit. Comput. 2021:1-13Majumdar S,

Nandi SK, Ghosal S et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=33552306 15. Innate Immune Cells and Hypertension: Neutrophils and Neutrophil

Extracellular Traps (NETs). Compr Physiol 2021; 11:1575-1589McCarthy CG,

Saha P, Golonka RM et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=33577121 16. Screening Possible Drug Molecules for Covid-19. The Example of Vanadium

(III/IV/V) Complex Molecules with Computational Chemistry and Molecular Docking. Comput Toxicol 2021:100157Vlasiou MC, Pafti KS.

17. Carboxypeptidase B blocks ex vivo activation of the anaphylatoxin-neutrophil

extracellular trap axis in neutrophils from COVID-19 patients. Crit Care 2021;

25:51Zhang Y, Han K, Du C et al. http://www.ncbi.nlm.nih.gov/pubmed/? term=33557911

18. Characteristics of Viral Shedding in Respiratory Samples and Speciﬁc

Antibodies Production in 564 COVID-19 Patients. Curr Med Sci 2021;

41:46-50Gong J, Dong H, Wang DK et al. http://www.ncbi.nlm.nih.gov/pubmed/? term=33582904

19. The Ineluctable Role of ACE-2 Receptors in SARS COV-2 Infection and Drug

Repurposing as a Plausible SARS COV-2 Therapy : A Concise Treatise. Curr.

Mol. Med. 2021; Joseph S, Nair B, Nath LR. http://www.ncbi.nlm.nih.gov/pubmed/? term=33563197

20. The computational intervention of macrolide antibiotics in the treatment of

COVID-19. Curr. Pharm. Des. 2021; Anwar F, Altayb HN, Al-Abbasi FA et al.

21. Novel SARS-CoV-2 Variant Identiﬁed in Travelers from Brazil to Japan. Emerg Infect Dis 2021; 27Fujino T, Nomoto H, Kutsuna S et al.

22. Imported SARS-COV-2 Variant P.1 Detected in Traveler Returning from Brazil

to Italy. Emerg Infect Dis 2021; 27Maggi F, Novazzi F, Genoni A et al.

23. Tracing the origins of SARS-COV-2 in coronavirus phylogenies: a review. Environ. Chem. Lett. 2021:1-17Sallard E, Halloy J, Casane D et al.

(8)

24. Reply to: A key role for vitamin D binding protein in COVID-19? Eur. J. Nutr. 2021; Arab-Ahmadi M, Behnam B, Abrishami A, Sanei-Taheri M.

25. A pressor dose of angiotensin II has no inﬂuence on the

angiotensin-converting enzyme 2 and other molecules associated with SARS-CoV-2

infection in mice. Faseb j 2021; 35:e21419Wang Y, Takeshita H, Yamamoto K et al.

26. Elucidating the Interactions Between Heparin/Heparan Sulfate and

SARS-CoV-2-Related Proteins-An Important Strategy for Developing Novel Therapeutics for the COVID-19 Pandemic. Front Mol Biosci 2020; 7:628551Yu M, Zhang T,

Zhang W et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=33569392

27. The Spatial and Cell-Type Distribution of SARS-CoV-2 Receptor ACE2 in the

Human and Mouse Brains. Front. Neurol. 2020; 11:573095Chen R, Wang K, Yu J

28. Tissue Distribution of ACE2 Protein in Syrian Golden Hamster (Mesocricetus

auratus) and Its Possible Implications in SARS-CoV-2 Related Studies. Front.

Pharmacol. 2020; 11:579330Suresh V, Parida D, Minz AP et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=33568991

29. Targeting the SARS-CoV-2 3CL(pro) and NO/cGMP/PDE5 pathway in

COVID-19: a commentary on PDE5 inhibitors. Future Cardiol 2021; Shirvaliloo M.

30. Dual targeting of toll-like receptor 4 and angiotensin-converting enzyme 2:

a proposed approach to SARS-CoV-2 treatment. Future Microbiol. 2021;

Gadanec LK, Qaradakhi T, McSweeney KR et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=33569984

31. The molecular assessment of SARS-CoV-2 Nucleocapsid Phosphoprotein

variants among Indian isolates. Heliyon 2021; 7:e06167Azad GK.

32. COVID-19 immune signatures reveal stable antiviral T cell function despite

declining humoral responses. Immunity 2021; 54:340-354.e346Bonifacius A,

Tischer-Zimmermann S, Dragon AC et al. http://www.ncbi.nlm.nih.gov/pubmed/? term=33567252

33. Potential Interplay between Nrf2, TRPA1, and TRPV1 in Nutrients for the

Control of COVID-19. Int. Arch. Allergy Immunol. 2021:1-15Bousquet J, Czarlewski

W, Zuberbier T et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=33567446 34. COVID-19 as a worldwide selective event and bitter taste receptor

polymorphisms: An ecological correlational study. Int. J. Biol. Macromol. 2021;

Parsa S, Mogharab V, Ebrahimi M et al. http://www.ncbi.nlm.nih.gov/pubmed/? term=33582215

35. Nicotinic Acetylcholine Receptor Involvement in Inﬂammatory Bowel Disease

and Interactions with Gut Microbiota. Int J Environ Res Public Health 2021;

18Rueda Ruzafa L, Cedillo JL, Hone AJ. http://www.ncbi.nlm.nih.gov/pubmed/? term=33572734

36. The unbalanced p53/SIRT1 axis may impact lymphocyte homeostasis in

(9)

37. Tryptophan Metabolites and Aryl Hydrocarbon Receptor in Severe Acute

Respiratory Syndrome, Coronavirus-2 (SARS-CoV-2) Pathophysiology. Int J

Mol Sci 2021; 22Anderson G, Carbone A, Mazzoccoli G. http://www.ncbi.nlm.nih.gov/pubmed/?term=33562472

38. Understanding Viral Infection Mechanisms and Patient Symptoms for the

Development of COVID-19 Therapeutics. Int J Mol Sci 2021; 22Choi HM, Moon

SY, Yang HI, Kim KS. http://www.ncbi.nlm.nih.gov/pubmed/?term=33572274 39. Expression of the SARS-CoV-2 Receptor ACE2 and Proinﬂammatory

Cytokines Induced by the Periodontopathic Bacterium Fusobacterium nucleatum in Human Respiratory Epithelial Cells. Int J Mol Sci 2021;

22Takahashi Y, Watanabe N, Kamio N et al. http://www.ncbi.nlm.nih.gov/pubmed/? term=33572938

40. In Silico Investigation of the New UK (B.1.1.7) and South African (501Y.V2)

SARS-CoV-2 Variants with a Focus at the ACE2-Spike RBD Interface. Int J Mol

Sci 2021; 22Villoutreix BO, Calvez V, Marcelin AG, Khatib AM. http://www.ncbi.nlm.nih.gov/pubmed/?term=33567580

41. Soy Bean-Associated Endophytic Fungi as Potential Source for Anti-COVID-19

Metabolites supported by docking analysis. J. Appl. Microbiol. 2021; El-Hawary

SS, Mohammed R, Bahr HS et al. http://www.ncbi.nlm.nih.gov/pubmed/? term=33559270

42. Drug Repurposing for COVID-19 via Knowledge Graph Completion. J. Biomed. Inform. 2021:103696Zhang R, Hristovski D, Schutte D et al.

43. How Our Neanderthal Genes Affect the COVID-19 Mortality: Iran and Mongolia,

Two Countries with the Same SARS-CoV-2 Mutation Cluster but Different Mortality Rates. J Biomed Phys Eng 2021; 11:109-114Mortazavi SAR,

Kaveh-Ahangar K, Mortazavi SMJ et al. http://www.ncbi.nlm.nih.gov/pubmed/? term=33564646

44. Artiﬁcially expanded genetic information systems (AEGISs) as potent

inhibitors of the RNA-dependent RNA polymerase of the SARS-CoV-2. J Biomol

Struct Dyn 2021:1-17Jena NR, Pant S, Srivastava HK. http://www.ncbi.nlm.nih.gov/pubmed/?term=33565387

45. Targeting the N-terminal domain of the RNA-binding protein of the

SARS-CoV-2 with high afﬁnity natural compounds to abrogate the protein-RNA

interaction: a amolecular dynamics study. J Biomol Struct Dyn 2021:1-9Khan S,

Hussain Z, Safdar M et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=33554747 46. Hepatotropic Properties of SARS-CoV-2-Preliminary Results of

Cross-Sectional Observational Study from the First Wave COVID-19 Pandemic. J Clin

Med 2021; 10Wiśniewska H, Skonieczna-Żydecka K, Parczewski M et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=33572429

47. Relationship between betacoronaviruses and the endocrine system: a new key

to understand the COVID-19 pandemic-A comprehensive review. J. Endocrinol.

Invest. 2021; Piticchio T, Le Moli R, Tumino D, Frasca F. http://www.ncbi.nlm.nih.gov/pubmed/?term=33583003

(10)

48. S-variant SARS-CoV-2 lineage B1.1.7 is associated with signiﬁcantly higher

viral loads in samples tested by ThermoFisher TaqPath RT-qPCR. J Infect Dis

2021; Kidd M, Richter A, Best A et al. http://www.ncbi.nlm.nih.gov/pubmed/? term=33580259

49. Interaction of small molecules with the SARS-CoV-2 papain-like protease: In

silico studies and in vitro validation of protease activity inhibition using an enzymatic inhibition assay. J. Mol. Graph. Model. 2021; 104:107851Pitsillou E,

Liang J, Ververis K et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=33556646 50. Proteo-Genomic Analysis of SARS-CoV-2: A Clinical Landscape of

Single-Nucleotide Polymorphisms, COVID-19 Proteome, and Host Responses. J.

Proteome Res. 2021; Tushir S, Kamanna S, Nath SS et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=33555895

51. Clinical and laboratory evaluation of patients with SARS-CoV-2 pneumonia

treated with high-titer convalescent plasma. JCI Insight 2021; Donato ML, Park

S, Baker M et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=33571168 52. Coumarins and Quinolones as Effective Multiple Targeted Agents Versus

Covid-19: An in Silico Study. Med. Chem. 2021; Nejabat M, Ghodsi R, Hadizadeh

F. http://www.ncbi.nlm.nih.gov/pubmed/?term=33563156

53. Silence of the Lambs: The Immunological and Molecular Mechanisms of

COVID-19 in Children in Comparison with Adults. Microorganisms 2021;

9Cusenza F, Davino G, D'Alvano T et al. http://www.ncbi.nlm.nih.gov/pubmed/? term=33562210

54. Antibody binding epitope Mapping (AbMap) of hundred antibodies in a single

run. Mol. Cell. Proteomics 2021:100059Qi H, Ma M, Hu C et al.

55. Nanoluciferase complementation-based bioreporter reveals the importance of

N-linked glycosylation of SARS-CoV-2 Spike for viral entry. Mol. Ther. 2021;

Azad T, Singaravelu R, Taha Z et al. http://www.ncbi.nlm.nih.gov/pubmed/? term=33578036

56. In Silico Study of Polyunsaturated Fatty Acids as Potential SARS-CoV-2 Spike

Protein Closed Conformation Stabilizers: Epidemiological and Computational Approaches. Molecules 2021; 26Vivar-Sierra A, Araiza-Macías MJ,

Hernández-Contreras JP et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=33573088 57. Molecular Evolution of Human Coronavirus 229E in Hong Kong and a Fatal

COVID-19 Case Involving Coinfection with a Novel Human Coronavirus 229E Genogroup. mSphere 2021; 6Lau SKP, Lung DC, Wong EYM et al.

58. Amino acid sensing pathway: A major check point in the pathogenesis of

obesity and COVID-19. Obes Rev 2021:e13221Philips AM, Khan N.

59. Host Diversity and Potential Transmission Pathways of SARS-CoV-2 at the

Human-Animal Interface. Pathogens 2021; 10Hedman HD, Krawczyk E, Helmy YA

60. Quantum mechanical studies of the adsorption of Remdesivir, as an effective

drug for treatment of COVID-19, on the surface of pristine,

(11)

Dimens Syst Nanostruct 2021; 129:114668Bagheri Novir S, Aram MR. http://www.ncbi.nlm.nih.gov/pubmed/?term=33564274

61. Quantum mechanical studies of the adsorption of Remdesivir, as an effective

drug for treatment of COVID-19, on the surface of pristine,

COOH-functionalized and S-, Si- and Al- doped carbon nanotubes. Physica E Low

Dimens Syst Nanostruct 2021; 129:114668Novir SB, Aram MR. http://www.ncbi.nlm.nih.gov/pubmed/?term=33564274

62. Computational drug screening against the SARS-CoV-2 Saudi Arabia isolates

through a multiple-sequence alignment approach. Saudi J. Biol. Sci. 2021; Mok

PL, Koh AE, Farhana A et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=33551661 63. Single-cell transcriptomes of peripheral blood cells indicate and elucidate

severity of COVID-19. Sci China Life Sci 2021:1-11Xie X, Cheng X, Wang G et al.

64. Effect of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) on

reproductive system. Stem Cell Res 2021; 52:102189Wang N, Qin L, Ma L, Yan H.

65. P2Y14 Receptor as a Target for Neutrophilia Attenuation in Severe COVID-19

Cases: From Hematopoietic Stem Cell Recruitment and Chemotaxis to Thrombo-inﬂammation. Stem Cell Rev Rep 2021; Lintzmaier Petiz L, Glaser T,

Scharfstein J et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=33575962

66. The risk from SARS-CoV-2 to bat species in England and mitigation options

for conservation ﬁeld workers. Transbound Emerg Dis 2021; Common SM,

Shadbolt T, Walsh K, Sainsbury AW. http://www.ncbi.nlm.nih.gov/pubmed/? term=33570837

67. Immunogenicity and crossreactivity of antibodies to the nucleocapsid protein

of SARS-CoV-2: utility and limitations in seroprevalence and immunity studies.

Transl. Res. 2021; Dobaño C, Santano R, Jiménez A et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=33582244

68. Expression, puriﬁcation and immunological characterization of recombinant

nucleocapsid protein fragment from SARS-CoV-2. Virology 2021;

557:15-22Djukic T, Mladenovic M, Stanic-Vucinic D et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=33582454

69. The G614 pandemic SARS-CoV-2 variant is not more pathogenic than the

original D614 form in adult Syrian hamsters. Virology 2021; 556:96-100Stauft

CB, Lien CZ, Selvaraj P et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=33556653 70. Lower respiratory tract samples are reliable for severe acute respiratory

syndrome coronavirus 2 nucleic acid diagnosis and animal model study. Zool

Res 2021:1-9Tian RR, Yang CX, Zhang M et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=33554485

Biomarkers - Genetics (156 articles)

1. Risk assessment and prognostic aspect of coagulopathy in COVID-19. Adv Respir Med 2021; Rahman M, Rakhi NN. http://www.ncbi.nlm.nih.gov/pubmed/? term=33559122

(12)

2. The Usefulness Of SARS-CoV-2 Test-Positive Proportion As A Surveillance

Tool. Am. J. Epidemiol. 2021; Hitchings MDT, Dean NE, Garcia-Carreras B et al.

3. Association of ABO blood group with indices of disease severity and

multiorgan dysfunction in COVID-19. Anaesth Crit Care Pain Med

2021:100812Tonon D, Simeone P, Lagier D et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=33556587

4. Prostate Speciﬁc Antigen in COVID-19 patients. Andrology 2021; Di Vincenzo A, Busetto L, Vettor R, Rossato M. http://www.ncbi.nlm.nih.gov/pubmed/?

term=33580913

5. Clinical manifestations of blood cell parameters and inﬂammatory factors in

92 patients with COVID-19. Ann Transl Med 2021; 9:62Deng R, Wang C, Ye Y et

6. Detection of SARS-CoV-2 in the ocular surface in different phases of COVID-19

patients in Shanghai, China. Ann Transl Med 2021; 9:100Li M, Yang Y, He T et al.

7. "COVID-19/SARS-CoV-2 virus spike protein-related delayed inﬂammatory

reaction to hyaluronic acid dermal ﬁllers: a challenging clinical conundrum in diagnosis and treatment". Arch. Dermatol. Res. 2021:1-15Munavalli GG,

Guthridge R, Knutsen-Larson S et al. http://www.ncbi.nlm.nih.gov/pubmed/? term=33559733

8. SARS-CoV-2 genome and antibodies in breastmilk: a systematic review and

meta-analysis. Arch. Dis. Child. Fetal Neonatal Ed. 2021; Zhu F, Zozaya C, Zhou Q

9. COVID-19: molecular pathophysiology, genetic evolution and prospective

therapeutics-a review. Arch. Microbiol. 2021; Raj CTD, Kandaswamy DK, Danduga

R et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=33555378

10. Induced dysregulation of ACE2 by SARS-CoV-2 plays a key role in COVID-19

severity. Biomed. Pharmacother. 2021; 137:111363Mehrabadi ME, Hemmati R,

Tashakor A et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=33582450

11. Research Progress on the Cardiac Injury from ACE2 Targeting in SARS-CoV-2

Infection. Biomolecules 2021; 11Sun H, Su X, Huang L et al.

12. The association between clinical laboratory data and chest CT ﬁndings

explains disease severity in a large Italian cohort of COVID-19 patients. BMC

Infect. Dis. 2021; 21:157Canovi S, Besutti G, Bonelli E et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=33557778

13. Evaluation of patients with respiratory infections during the ﬁrst pandemic

wave in Germany: characteristics of COVID-19 versus non-COVID-19 patients.

BMC Infect. Dis. 2021; 21:167Fink N, Rueckel J, Kaestle S et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=33568104

14. Differences of blood cells, lymphocyte subsets and cytokines in COVID-19

patients with different clinical stages: a network meta-analysis. BMC Infect.

Dis. 2021; 21:156Yan W, Chen D, Bigambo FM et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=33557779

(13)

15. Predicting COVID-19 disease progression and patient outcomes based on

temporal deep learning. BMC Med. Inform. Decis. Mak. 2021; 21:45Sun C, Hong

S, Song M et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=33557818

16. Seroprevalence of antibodies to SARS-CoV-2 in healthcare workers: a

cross-sectional study. BMJ Open 2021; 11:e043584Ebinger JE, Botwin GJ, Albert CM et

17. False-negative RT-PCR for COVID-19 and a diagnostic risk score: a

retrospective cohort study among patients admitted to hospital. BMJ Open

2021; 11:e047110Gupta-Wright A, Macleod CK, Barrett J et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=33563629

18. Integrated network analysis reveals new genes suggesting COVID-19 chronic

effects and treatment. Brief. Bioinform. 2021; Pavel A, Del Giudice G, Federico A

19. Assessment of the risk of infection from SARS-CoV-2 for healthcare

workers-ﬁndings from practice. Bundesgesundheitsblatt, Gesundheitsforschung,

Gesundheitsschutz 2021; Pfenninger EG, Christ P, Neumüller M, Dinse-Lambracht A.

20. Time to SARS-CoV-2 clearance among patients with cancer and COVID-19. Cancer Med 2021; Xu W, Piper-Vallillo AJ, Bindal P et al.

21. Are RNA-Based Tests Sufﬁcient for COVID-19 Diagnosis? An Inspiration of

Three Asymptomatic Cases. Cell Transplant. 2021; 30:963689720985453Hu T, Liu

X, Yin Q et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=33555211 22. Point of care detection of COVID-19: Advancement in biosensing and

diagnostic methods. Chem. Eng. J. 2021; 414:128759Suleman S, Shukla SK,

Malhotra N et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=33551668

23. SARS-CoV-2 serologic tests: do not forget the good laboratory practice. Clin Chem Lab Med 2020; Aloisio E, Falvella FS, Carnevale A, Panteghini M.

24. Variability of cycle threshold values in an external quality assessment scheme

for detection of the SARS-CoV-2 virus genome by RT-PCR. Clin Chem Lab Med

2020; Buchta C, Görzer I, Chiba P et al. http://www.ncbi.nlm.nih.gov/pubmed/? term=33554519

25. Searching for a role of procalcitonin determination in COVID-19: a study on a

selected cohort of hospitalized patients. Clin Chem Lab Med 2020;

59:433-440Dolci A, Robbiano C, Aloisio E et al. http://www.ncbi.nlm.nih.gov/pubmed/? term=33554505

26. Prevalence of SARS-CoV-2 antibodies in health care personnel of two acute

care hospitals in Linz, Austria. Clin Chem Lab Med 2021; Egger M, Bundschuh C,

Wiesinger K et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=33554543

27. An original multiplex method to assess ﬁve different SARS-CoV-2 antibodies. Clin Chem Lab Med 2020; Favresse J, Brauner J, Bodart N et al.

28. Performance of three automated SARS-CoV-2 antibody assays and relevance

(14)

E, Jansens H, Matheeussen V et al. http://www.ncbi.nlm.nih.gov/pubmed/? term=33554506

29. Evaluation of four commercial, fully automated SARS-CoV-2 antibody tests

suggests a revision of the Siemens SARS-CoV-2 IgG assay. Clin Chem Lab Med

2021; Irsara C, Egger AE, Prokop W et al. http://www.ncbi.nlm.nih.gov/pubmed/? term=33554557

30. Cytokine "storm", cytokine "breeze", or both in COVID-19? Clin Chem Lab Med 2020; Lippi G, Plebani M. http://www.ncbi.nlm.nih.gov/pubmed/?term=33554554 31. Very high SARS-CoV-2 load at the emergency department presentation

strongly predicts the risk of admission to the intensive care unit and death.

Clin Chem Lab Med 2021; Mancini N, Clementi N, Ferrarese R et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=33577724

32. Hemocytometric characteristics of COVID-19 patients with and without

cytokine Storm syndrome on the Sysmex XN-10 hematology analyzer. Clin

Chem Lab Med 2020; Martens RJH, van Adrichem AJ, Mattheij NJA et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=33554540

33. Vitamin D levels and intensive care unit outcomes of a cohort of critically ill

COVID-19 patients. Clin Chem Lab Med 2021; Orchard L, Baldry M, Nasim-Mohi M

34. Parallel testing of 241 clinical nasopharyngeal swabs for the detection of

SARS-CoV-2 virus on the Cepheid Xpert Xpress SARS-CoV-2 and the Roche cobas SARS-CoV-2 assays. Clin Chem Lab Med 2020; 59:e45-e48Tham JWM, Ng

SC, Chai CN et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=33554503 35. Evaluation of dried blood spots as alternative sampling material for

serological detection of anti-SARS-CoV-2 antibodies using established ELISAs. Clin Chem Lab Med 2021; Weisser H, Steinhagen K, Höcker R et al.

36. D-dimer daily continuous tendency predicts the short-term prognosis for

COVID-19 independently: A retrospective study from Northeast China. Clin.

Hemorheol. Microcirc. 2021; Xing Y, Yang W, Jin Y et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=33554893

37. Modeling effectiveness of testing strategies to prevent COVID-19 in nursing

homes -United States, 2020. Clin Infect Dis 2021; See I, Paul P, Slayton RB et al.

38. Severe and Irreversible Pancytopenia Associated With SARS-CoV-2 Bone

Marrow Infection in a Patient With Waldenstrom Macroglobulinemia. Clin.

Lymphoma Myeloma Leuk. 2021; Velier M, Priet S, Appay R et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=33563581

39. Chemokines and chemokine receptors during COVID-19 infection. Comput Struct Biotechnol J 2021; 19:976-988Khalil BA, Elemam NM, Maghazachi AA. http://www.ncbi.nlm.nih.gov/pubmed/?term=33558827

40. SARS-CoV-2 pneumonia-receptor binding and lung immunopathology: a

narrative review. Crit Care 2021; 25:53Menezes MCS, Pestana DVS, Gameiro GR

41. Carboxypeptidase B blocks ex vivo activation of the anaphylatoxin-neutrophil

(15)

25:51Zhang Y, Han K, Du C et al. http://www.ncbi.nlm.nih.gov/pubmed/? term=33557911

42. Diagnostic Accuracy of Electro-Chemiluminescence Immunoassay

Anti-SARS-CoV-2 Serological Test. Cureus 2021; 13:e12588Afzal N, Tariq N, Raza S, Shakeel

D. http://www.ncbi.nlm.nih.gov/pubmed/?term=33575149

43. Antineutrophil Cytoplasmic Antibody-Associated Glomerulonephritis in a

Case of Scleroderma After Recent Diagnosis With COVID-19. Cureus 2021;

13:e12485Jalalzadeh M, Valencia-Manrique JC, Boma N et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=33564500

44. Characteristics of Viral Shedding in Respiratory Samples and Speciﬁc

Antibodies Production in 564 COVID-19 Patients. Curr Med Sci 2021;

41:46-50Gong J, Dong H, Wang DK et al. http://www.ncbi.nlm.nih.gov/pubmed/? term=33582904

45. Prolonged SARS-CoV-2-RNA Detection from Nasopharyngeal Swabs in an

Oncologic Patient: What Impact on Cancer Treatment? Curr. Oncol. 2021;

28:847-852Ferrari A, Trevenzoli M, Sasset L et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=33567626

46. Recent Advancement in SARS-CoV-2 Diagnosis, Treatment, and Vaccine

Formulation: a New Paradigm of Nanotechnology in Strategic Combating of COVID-19 Pandemic. Curr Pharmacol Rep 2021:1-14Upadhyay SK, Dan S, Girdhar

M, Rastogi K. http://www.ncbi.nlm.nih.gov/pubmed/?term=33552875

47. The prognostic role of IL-10 in non-severe COVID-19 with chemosensory

dysfunction. Cytokine 2021; 141:155456Locatello LG, Bruno C, Maggiore G et al.

48. The roles and potential therapeutic implications of C5a in the pathogenesis of

COVID-19-associated coagulopathy. Cytokine Growth Factor Rev. 2020; Li J, Liu

B. http://www.ncbi.nlm.nih.gov/pubmed/?term=33558131

49. Interferons and other cytokines, genetics and beyond in COVID-19 and

autoimmunity. Cytokine Growth Factor Rev. 2021; Opdenakker G, Van Damme J.

50. Sample pooling is efﬁcient in PCR testing of SARS-CoV-2: a study in 7400

healthcare professionals. Diagn. Microbiol. Infect. Dis. 2021; 100:115330Estévez

A, Catalán P, Alonso R et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=33571860 51. Rapid community point-of-care testing for COVID-19 (RAPTOR-C19): protocol

for a platform diagnostic study. Diagn Progn Res 2021; 5:4Nicholson BD,

Hayward G, Turner PJ et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=33557927 52. Making sense of rapid antigen testing in severe acute respiratory syndrome

coronavirus 2 (SARS-CoV-2) diagnostics. Diagnosis (Berl) 2020; Mattiuzzi C,

Henry BM, Lippi G. http://www.ncbi.nlm.nih.gov/pubmed/?term=33554523 53. Clinical assessment of the Roche SARS-CoV-2 rapid antigen test. Diagnosis

(Berl) 2021; Salvagno GL, Gianﬁlippi G, Bragantini D et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=33554511

54. Serological Test to Determine Exposure to SARS-CoV-2: ELISA Based on the

Receptor-Binding Domain of the Spike Protein (S-RBD(N318-V510)) Expressed in Escherichia coli. Diagnostics (Basel) 2021; 11Márquez-Ipiña AR,

(16)

González-González E, Rodríguez-Sánchez IP et al. http://www.ncbi.nlm.nih.gov/pubmed/? term=33578665

55. Passive Microwave Radiometry for the Diagnosis of Coronavirus Disease 2019

Lung Complications in Kyrgyzstan. Diagnostics (Basel) 2021; 11Osmonov B,

Ovchinnikov L, Galazis C et al. http://www.ncbi.nlm.nih.gov/pubmed/? term=33562419

56. Early life factors and COVID-19 infection in England: A prospective analysis of

UK Biobank participants. Early Hum. Dev. 2021; 155:105326Didikoglu A,

Maharani A, Pendleton N et al. http://www.ncbi.nlm.nih.gov/pubmed/? term=33578220

57. Simpler and faster Covid-19 testing: Strategies to streamline SARS-CoV-2

molecular assays. EBioMedicine 2021; 64:103236Panpradist N, Wang Q, Ruth PS

58. Novel SARS-CoV-2 Variant Identiﬁed in Travelers from Brazil to Japan. Emerg Infect Dis 2021; 27Fujino T, Nomoto H, Kutsuna S et al.

59. Imported SARS-COV-2 Variant P.1 Detected in Traveler Returning from Brazil

to Italy. Emerg Infect Dis 2021; 27Maggi F, Novazzi F, Genoni A et al.

60. Hyperglycemia is Associated With Increased Mortality in Critically Ill Patients

With COVID-19. Endocr. Pract. 2021; Mazori AY, Bass IR, Chan L et al.

61. Sick Euthyroid Syndrome on Presentation of Patients With COVID-19: A

Potential Marker for Disease Severity. Endocr. Pract. 2021; Schwarz Y, Percik R,

Oberman B et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=33551316

62. Seroprevalence of antibodies against SARS-CoV-2 among health care workers

in a pediatric monographic hospital in Madrid (Spain). Enferm. Infecc. Microbiol.

Clin. 2021; Escribano Ceruelo E, Espinel Ruíz MA, Ortega López-Peláez M et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=33563481

63. MR-proADM as marker of endotheliitis predicts COVID-19 severity. Eur. J. Clin. Invest. 2021:e13511García de Guadiana Romualdo L, Calvo Nieves MD, Rodríguez Mulero MD et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=33569769

64. SARS-CoV-2 re-infection risk in Austria. Eur. J. Clin. Invest. 2021:e13520Pilz S, Chakeri A, Ioannidis JP et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=33583018 65. Unraveled roles of hyaluronan in severe COVID-19. Excli j 2021;

20:117-125Ontong P, Prachayasittikul V. http://www.ncbi.nlm.nih.gov/pubmed/? term=33564281

66. Coagulopathy is associated with multiple organ damage and prognosis of

COVID-19. Excli j 2021; 20:174-191Zhang R, Liu Y, Zhang B et al.

67. Ultimate COVID-19 Detection Protocol Based on Saliva Sampling and qRT-PCR

with Risk Probability Assessment. Exp Neurobiol 2021; Won J, Kazan HH, Kwon

J et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=33556920

68. Cardiac Biomarker Levels and Their Prognostic Values in COVID-19 Patients

(17)

7:599096Yu JS, Pan NN, Chen RD et al. http://www.ncbi.nlm.nih.gov/pubmed/? term=33553255

69. Analysis of COVID-19-Related RT-qPCR Test Results in Hungary:

Epidemiology, Diagnostics, and Clinical Outcome. Front Med (Lausanne) 2020;

7:625673Gombos K, Földi M, Kiss S et al. http://www.ncbi.nlm.nih.gov/pubmed/? term=33575263

70. Short-Term Variations in Neutrophil-to-Lymphocyte and Urea-to-Creatinine

Ratios Anticipate Intensive Care Unit Admission of COVID-19 Patients in the Emergency Department. Front Med (Lausanne) 2020; 7:625176Solimando AG,

Susca N, Borrelli P et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=33553217 71. Can GPR4 Be a Potential Therapeutic Target for COVID-19? Front Med

(Lausanne) 2020; 7:626796Yang LV, Oppelt KA, Thomassen MJ et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=33553219

72. Serum Prealbumin Concentrations, COVID-19 Severity, and Mortality: A

Systematic Review and Meta-Analysis. Front Med (Lausanne) 2021;

8:638529Zinellu A, Mangoni AA. http://www.ncbi.nlm.nih.gov/pubmed/? term=33575267

73. Development of a Fast SARS-CoV-2 IgG ELISA, Based on Receptor-Binding

Domain, and Its Comparative Evaluation Using Temporally Segregated Samples From RT-PCR Positive Individuals. Front. Microbiol. 2020;

11:618097Mehdi F, Chattopadhyay S, Thiruvengadam R et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=33552028

74. The Biosafety and Risk Management in Preparation and Processing of

Cerebrospinal Fluid and Other Neurological Specimens With Potential

Coronavirus Infection. Front. Neurol. 2020; 11:613552Chen CC, Chiang PC, Chen

TH. http://www.ncbi.nlm.nih.gov/pubmed/?term=33551970

75. The Spatial and Cell-Type Distribution of SARS-CoV-2 Receptor ACE2 in the

Human and Mouse Brains. Front. Neurol. 2020; 11:573095Chen R, Wang K, Yu J

76. Sensitivity of SARS-CoV-2 Detection With Nasopharyngeal Swabs. Front Public Health 2020; 8:593491Clerici B, Muscatello A, Bai F et al.

77. Vitamin D Deﬁciency as an Important Biomarker for the Increased Risk of

Coronavirus (COVID-19) in People From Black and Asian Ethnic Minority Groups. Front Public Health 2020; 8:613462Pardhan S, Smith L, Sapkota RP.

78. A peptide-based assay discriminates individual antibody response to

SARS-CoV-2. Genes Dis 2021; Polvere I, Voccola S, Cardinale G et al.

79. Microbiota-derived short-chain fatty acids do not interfere with SARS-CoV-2

infection of human colonic samples. Gut Microbes 2021; 13:1-9Pascoal LB,

Rodrigues PB, Genaro LM et al. http://www.ncbi.nlm.nih.gov/pubmed/? term=33550892

80. The molecular assessment of SARS-CoV-2 Nucleocapsid Phosphoprotein

variants among Indian isolates. Heliyon 2021; 7:e06167Azad GK.

(18)

81. IL-6 and IL-10 as predictors of disease severity in COVID-19 patients: results

from meta-analysis and regression. Heliyon 2021; 7:e06155Dhar SK, K V,

Damodar S et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=33553782

82. Association of Vitamin D Status with COVID-19 Infection and Mortality in the

Asia Paciﬁc region: A Cross-Sectional Study. Indian J. Clin. Biochem.

2021:1-6Yadav D, Birdi A, Tomo S et al. http://www.ncbi.nlm.nih.gov/pubmed/? term=33551585

83. Presence of SARS-CoV-2 RNA in Semen-Cohort Study in the United States

COVID-19 Positive Patients. Infect Dis Rep 2021; 13:96-101Machado B, Barcelos

Barra G, Scherzer N et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=33557147 84. Time to Negative SARS-CoV-2 PCR Should Not Delay Care Among Patients

With Inﬂammatory Bowel Diseases. Inﬂamm. Bowel Dis. 2021; Winter RW,

Ananthakrishnan A, Burke KE et al. http://www.ncbi.nlm.nih.gov/pubmed/? term=33570095

85. Serological Proﬁle of Children and Young Adults with at Least One

SARS-CoV-2 Positive Cohabitant: An Observational Study. Int J Environ Res Public Health

2021; 18Farronato M, Dolci C, Boccalari E et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=33557402

86. SARS-CoV-2: An Update on Genomics, Risk Assessment, Potential

Therapeutics and Vaccine Development. Int J Environ Res Public Health 2021;

18Mehmood I, Ijaz M, Ahmad S et al. http://www.ncbi.nlm.nih.gov/pubmed/? term=33567746

87. Saliva is a reliable and accessible source for the detection of SARS-CoV-2. Int J Infect Dis 2021; Herrera LA, Hidalgo-Miranda A, Reynoso-Noverón N et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=33581365

88. Prospective Study of 1,308 Nasopharyngeal Swabs from 1,033 Patients using

the LUMIPULSE SARS-CoV-2 Antigen Test: Comparison with RT-qPCR. Int J

Infect Dis 2021; Hirotsu Y, Maejima M, Shibusawa M et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=33556612

89. Speciﬁcity testing by point prevalence as a simple assessment strategy using

the Roche Elecsys® Anti-SARS-CoV-2 immunoassay. Int J Infect Dis 2021; Kittel

M, Findeisen P, Muth MC et al. http://www.ncbi.nlm.nih.gov/pubmed/? term=33578017

90. The relationship between serum erythropoietin, hepcidin, and haptoglobin

levels with disease severity and other biochemical values in patients with COVID-19. Int. J. Lab. Hematol. 2021; Yağcı S, Serin E, Acicbe Ö et al.

91. Tryptophan Metabolites and Aryl Hydrocarbon Receptor in Severe Acute

Respiratory Syndrome, Coronavirus-2 (SARS-CoV-2) Pathophysiology. Int J

Mol Sci 2021; 22Anderson G, Carbone A, Mazzoccoli G. http://www.ncbi.nlm.nih.gov/pubmed/?term=33562472

92. ERAP1 and ERAP2 Enzymes: A Protective Shield for RAS against COVID-19? Int J Mol Sci 2021; 22D'Amico S, Tempora P, Lucarini V et al.

93. Protein Expression of Angiotensin-Converting Enzyme 2 (ACE2) is

(19)

Shults NV, Gychka SG et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=33567524 94. In Silico Investigation of the New UK (B.1.1.7) and South African (501Y.V2)

SARS-CoV-2 Variants with a Focus at the ACE2-Spike RBD Interface. Int J Mol

Sci 2021; 22Villoutreix BO, Calvez V, Marcelin AG, Khatib AM. http://www.ncbi.nlm.nih.gov/pubmed/?term=33567580

95. Baseline characteristics and changes of biomarkers in disease course predict

prognosis of patients with COVID-19. Intern Emerg Med 2021:1-8Li T, Wang X,

Zhuang X et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=33565034

96. SARS-CoV-2 is not found in the sweat of COVID-19 positive patients. Ir. J. Med. Sci. 2021; Arslan B, Bercin S, Aydogan S et al.

97. SARS-CoV-2 Infection and Viral Load are Associated with the Upper

Respiratory Tract Microbiome. J Allergy Clin Immunol 2021; Rosas-Salazar C,

Kimura KS, Shilts MH et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=33577896 98. Sensitive tracking of circulating viral RNA through all stages of SARS-CoV-2

infection. J. Clin. Invest. 2021; Huang Z, Ning B, Yang HS et al.

99. Differential diagnosis of coronavirus disease 2019 pneumonia or inﬂuenza A

pneumonia by clinical characteristics and laboratory ﬁndings. J. Clin. Lab.

Anal. 2021:e23685Lv DF, Ying QM, He YW et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=33576536

100. Pseudothrombocytopenia-A Review on Causes, Occurrence and Clinical

Implications. J Clin Med 2021; 10Lardinois B, Favresse J, Chatelain B et al.

101. Comparing saliva and nasopharyngeal swab specimens in the detection of

COVID-19: A systematic review and meta-analysis. J Dent Sci 2021; Nasiri K,

Dimitrova A. http://www.ncbi.nlm.nih.gov/pubmed/?term=33558826

102. The cytokine storm and thyroid hormone changes in COVID-19. J. Endocrinol. Invest. 2021:1-14Croce L, Gangemi D, Ancona G et al.

103. Transmission of SARS-CoV-2 among healthcare workers and patients in a

teaching hospital in the Netherlands conﬁrmed by whole genome sequencing.

J Hosp Infect 2021; Paltansing S, Sikkema RS, Man SJ et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=33571558

104. Concerns regarding the sensitivity of the OptiGene direct SARS-CoV-2 LAMP

assay and its suitability for use in at-risk groups and hospital staff. J Infect

2021; Wilson-Davies ESW, Mahanama AIK, Samaraweera B et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=33573779

105. S-variant SARS-CoV-2 lineage B1.1.7 is associated with signiﬁcantly higher

viral loads in samples tested by ThermoFisher TaqPath RT-qPCR. J Infect Dis

2021; Kidd M, Richter A, Best A et al. http://www.ncbi.nlm.nih.gov/pubmed/? term=33580259

106. Neopterin: A Promising Candidate Biomarker for Severe COVID-19. J Inﬂamm Res 2021; 14:245-251Hailemichael W, Kiros M, Akelew Y et al.

(20)

107. The promise of direct-to-consumer COVID-19 testing: ethical and regulatory

issues. J Law Biosci 2020; 7:lsaa069Kalokairinou L, Zettler PJ, Nagappan A et al.

108. SARS-CoV-2 detection in human milk: a systematic review. J Matern Fetal Neonatal Med 2021:1-8Kumar J, Meena J, Yadav A, Kumar P.

109. Craniofacial Pain in COVID-19 Patients with Diabetes Mellitus: Clinical and

Laboratory Description of Twenty-One Cases. J Med Virol 2021; Badrah M, Riad

A, Kassem I et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=33570190 110. Craniofacial pain in COVID-19 patients with diabetes mellitus: Clinical and

laboratory description of 21 cases. J Med Virol 2021; Badrah M, Riad A, Kassem

I et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=33570190

111. Comprehensive Clinic, Laboratory and Instrumental Evaluation of Children

with COVID-19: A 6-Months Prospective Study. J Med Virol 2021; Isoldi S,

Mallardo S, Marcellino A et al. http://www.ncbi.nlm.nih.gov/pubmed/? term=33570199

112. Diagnosis value of SARS-CoV-2 antigen/antibody combined testing using

rapid diagnostic tests at hospital admission. J Med Virol 2021; Veyrenche N,

Bolloré K, Pisoni A et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=33554363 113. Diagnosis value of SARS-CoV-2 antigen or antibody combined testing using

rapid diagnostic tests at hospital admission. J Med Virol 2021; Veyrenche N,

Bolloré K, Pisoni A et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=33554363 114. Cerebrospinal ﬂuid in COVID-19: A systematic review of the literature. J Neurol

Sci 2021; 421:117316Lewis A, Frontera J, Placantonakis DG et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=33561753

115. Transient benign hyperphosphatasemia due to COVID-19: the ﬁrst case report. J. Pediatr. Endocrinol. Metab. 2020; Erat T, Atar M, Kontbay T.

116. Proteo-Genomic Analysis of SARS-CoV-2: A Clinical Landscape of

Single-Nucleotide Polymorphisms, COVID-19 Proteome, and Host Responses. J.

Proteome Res. 2021; Tushir S, Kamanna S, Nath SS et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=33555895

117. Biomarkers of COVID-19 severity may not serve patients with polycystic ovary

syndrome. J Transl Med 2021; 19:63Moin ASM, Nandakumar M, Sathyapalan T et

118. Clinical and laboratory evaluation of patients with SARS-CoV-2 pneumonia

treated with high-titer convalescent plasma. JCI Insight 2021; Donato ML, Park

S, Baker M et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=33571168

119. Increased serum amylase and/or lipase in coronavirus disease 2019

(COVID-19) patients: Is it really pancreatic injury? JGH Open 2021; 5:190-192Pribadi RR,

Simadibrata M. http://www.ncbi.nlm.nih.gov/pubmed/?term=33553654

120. Seroepidemiological Survey of the Antibody for Severe Acute Respiratory

Syndrome Coronavirus 2 with Neutralizing Activity at Hospitals: A Cross-sectional Study in Hyogo Prefecture, Japan. Jma j 2021; 4:41-49Furukawa K, Arii

(21)

121. Comparison of the Diagnostic Value of Immunochromatography Kits in

Corona Virus Disease 2019 Patients: A Prospective Pilot Study. Jma j 2021;

4:32-40Mitsunaga T, Seki Y, Yoshioka M et al. http://www.ncbi.nlm.nih.gov/pubmed/? term=33575501

122. SARS-CoV-2 Antibody Seroprevalence Among Maintenance Dialysis Patients

in the United States. Kidney Med 2021; Walker AG, Sibbel S, Wade C et al.

123. CSF leak after COVID-19 nasopharyngeal swab: a case report. Laryngoscope 2021; Paquin R, Ryan L, Vale FL et al. http://www.ncbi.nlm.nih.gov/pubmed/? term=33577104

124. Screening of severe acute respiratory syndrome coronavirus-2 infection

during labor and delivery using polymerase chain reaction and

immunoglobulin testing. Life Sci 2021; 271:119200Savirón-Cornudella R, Villalba

A, Esteban LM et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=33577855 125. SARS-CoV-2 Seroprevalence in Healthcare Workers of Kaunas Hospitals

during the First Wave of the COVID-19 Pandemic. Medicina (Kaunas) 2021;

57Pereckaitė L, Dambrauskienė A, Urbonienė D et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=33562085

126. Electrochemical Biosensors for the Detection of SARS-CoV-2 and Other

Viruses. Micromachines (Basel) 2021; 12Imran S, Ahmadi S, Kerman K.

127. Do Blood Eosinophils Predict in-Hospital Mortality or Severity of Disease in

SARS-CoV-2 Infection? A Retrospective Multicenter Study. Microorganisms

2021; 9Le Borgne P, Abensur Vuillaume L, Alamé K et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=33567583

128. Antibody binding epitope Mapping (AbMap) of hundred antibodies in a single

run. Mol. Cell. Proteomics 2021:100059Qi H, Ma M, Hu C et al.

129. Molecular Evolution of Human Coronavirus 229E in Hong Kong and a Fatal

COVID-19 Case Involving Coinfection with a Novel Human Coronavirus 229E Genogroup. mSphere 2021; 6Lau SKP, Lung DC, Wong EYM et al.

130. Latent class cluster analysis identiﬁed hidden headache phenotypes in

COVID-19: impact of pulmonary inﬁltration and IL-6. Neurol Sci

2021:1-9Karadaş Ö, Öztürk B, Sonkaya AR et al. http://www.ncbi.nlm.nih.gov/pubmed/? term=33559789

131. Cytokine and Chemokine Levels in Coronavirus Disease 2019 Convalescent

Plasma. Open Forum Infect Dis 2021; 8:ofaa574Bonny TS, Patel EU, Zhu X et al.

132. COVID-19 Preprocedural Testing: What About the False Positives? Otolaryngol Head Neck Surg 2021:194599821995109Hill CJ, Meyer CD, Elrod MG, Capra GG. http://www.ncbi.nlm.nih.gov/pubmed/?term=33560178

133. Cochrane corner: universal screening for SARS-CoV-2 infection. Pan Afr. Med. J. 2020; 37:48Ndwandwe D, Mathebula L, Adetokunboh O et al.

(22)

134. Evaluation of two ﬂuorescence immunoassays for the rapid detection of

SARS-CoV-2 antigen-new tool to detect infective COVID-19 patients. PeerJ

2021; 9:e10801Porte L, Legarraga P, Iruretagoyena M et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=33552746

135. Rotational Thromboelastometry (ROTEM) Proﬁling of COVID-19 Patients. Platelets 2021:1-7Mitrovic M, Sabljic N, Cvetkovic Z et al.

136. COVID-19 detection by dogs: from physiology to ﬁeld application-a review

article. Postgrad. Med. J. 2021; Sakr R, Ghsoub C, Rbeiz C et al.

137. Quantifying asymptomatic infection and transmission of COVID-19 in New

York City using observed cases, serology, and testing capacity. Proc Natl Acad

Sci U S A 2021; 118Subramanian R, He Q, Pascual M. http://www.ncbi.nlm.nih.gov/pubmed/?term=33571106

138. Dissecting lipid metabolism alterations in SARS-CoV-2. Prog. Lipid Res. 2021:101092Casari I, Manfredi M, Metharom P, Falasca M.

139. Polymerase-chain reaction testing to prevent hospital-acquired severe acute

respiratory syndrome coronavirus 2 infection in Shinjuku, an epicenter in Tokyo: The Tokyo Women's Medical University model. Respir Investig 2021;

Arimura K, Tagaya E, Kikuchi K et al. http://www.ncbi.nlm.nih.gov/pubmed/? term=33579647

140. The real-time reverse transcription-polymerase chain reaction threshold cycle

values for severe acute respiratory syndrome coronavirus 2 predict the prognosis of coronavirus disease 2019 pneumonia. Respir Investig 2021;

Fukushima T, Kabata H, Yamamoto R et al. http://www.ncbi.nlm.nih.gov/pubmed/? term=33582075

141. [Immune thrombocytopenia preceded by asymptomatic COVID-19 infection]. Rinsho Ketsueki 2021; 62:58-60Ochiai T, Ando J, Harada S et al.

142. Guidelines and Safety Considerations in the Laboratory Diagnosis of

SARS-CoV-2 Infection: A Prerequisite Study for Health Professionals. Risk Manag.

Healthc. Policy 2021; 14:379-389Asrani P, Hussain A, Nasreen K et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=33568956

143. Single-cell transcriptomes of peripheral blood cells indicate and elucidate

severity of COVID-19. Sci China Life Sci 2021:1-11Xie X, Cheng X, Wang G et al.

144. An accurate, high-speed, portable bifunctional electrical detector for

COVID-19. Sci China Mater 2021; 64:739-747Ke G, Su D, Li Y et al.

145. The fate of SARS-COV-2 in WWTPS points out the sludge line as a suitable

spot for detection of COVID-19. Sci Total Environ 2021; 772:145268Balboa S,

Mauricio-Iglesias M, Rodriguez S et al. http://www.ncbi.nlm.nih.gov/pubmed/? term=33556806

146. Selecting COVID-19 Convalescent Plasma for Neutralizing Antibody Potency

(23)

Meyer E, Simmons G, Grebe E et al. http://www.ncbi.nlm.nih.gov/pubmed/? term=33554362

147. SARS-CoV-2 Seroprevalence Post-First Wave among Primary Care Physicians

in Catania (Italy). Trop Med Infect Dis 2021; 6Ledda C, Carrasi F, Longombardo MT

148. [Results of preoperative SARS-CoV-2 testing in the coronavirus pandemic]. Urologe A 2021:1-5Rassweiler-Seyfried MC, Miethke T, Becker KP, Siegel F. http://www.ncbi.nlm.nih.gov/pubmed/?term=33559693

149. Localized and Systemic Immune Responses against SARS-CoV-2 Following

Mucosal Immunization. Vaccines (Basel) 2021; 9Chandrasekar SS, Phanse Y,

Hildebrand RE et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=33562141 150. Evaluation of SARS-CoV-2 antigen-based rapid diagnostic kits in Pakistan:

formulation of COVID-19 national testing strategy. Virol J 2021; 18:34Saeed U,

Uppal SR, Piracha ZZ et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=33581714 151. Expression, puriﬁcation and immunological characterization of recombinant

nucleocapsid protein fragment from SARS-CoV-2. Virology 2021;

557:15-22Djukic T, Mladenovic M, Stanic-Vucinic D et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=33582454

152. SARS Coronavirus-2 Microneutralisation and Commercial Serological Assays

Correlated Closely for Some but Not All Enzyme Immunoassays. Viruses 2021;

13Walker GJ, Naing Z, Ospina Stella A et al. http://www.ncbi.nlm.nih.gov/pubmed/? term=33557418

153. ABO blood group and COVID-19: a review on behalf of the ISBT COVID-19

working group. Vox Sang 2021; Goel R, Bloch EM, Pirenne F et al.

154. Pooled testing conserves SARS-CoV-2 laboratory resources and improves test

turn-around time: experience on the Kenyan Coast. Wellcome Open Res 2020;

5:186Agoti CN, Mutunga M, Lambisia AW et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=33134555

155. COMPARISON OF MOLECULAR AND SEROLOGICAL TESTS FOR SEVERE

ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) IN POST-EXPOSURE EMPLOYEES OF THE NEPHROLOGY DEPARTMENT. Wiad. Lek.

2020; 73:2572-2575Kwiatkowska M, Chomicka I, Malyszko J. http://www.ncbi.nlm.nih.gov/pubmed/?term=33577470

156. Lower respiratory tract samples are reliable for severe acute respiratory

syndrome coronavirus 2 nucleic acid diagnosis and animal model study. Zool

Res 2021:1-9Tian RR, Yang CX, Zhang M et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=33554485

Children (41 articles)

1. The impact of COVID-19 lockdown on infectious diseases epidemiology: The

experience of a tertiary Italian Pediatric Emergency Department. Am J Emerg

Med 2021; 43:115-117Rotulo GA, Percivale B, Molteni M et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=33556796

(24)

2. Acute acral eruptions in children during the COVID-19 pandemic:

Characteristics of 103 children and their family clusters. Ann. Dermatol.

Venereol. 2021; Hubiche T, Phan A, Leducq S et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=33551211

3. COVID-19 pandemic: health inequities in children and youth. Arch. Dis. Child. 2021; Kyeremateng R, Oguda L, Asemota O. http://www.ncbi.nlm.nih.gov/pubmed/? term=33574027

4. The Critical Need for Pooled Data on COVID-19 in African Children: An

AFREhealth Call for Action through Multi-Country Research Collaboration. Clin

Infect Dis 2021; Sam-Agudu NA, Rabie H, Pipo MT et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=33580256

5. Clinical Presentation and Successful Management of an Infant With Down

Syndrome and COVID-19 in Riyadh, Saudi Arabia. Cureus 2021;

13:e13188Alsahabi I, Alobaidi A, Alahmari AS et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=33575158

6. A Simulation-Based Program for Preparedness for COVID-19 at a Pediatric

Tertiary Hospital in Saudi Arabia. Cureus 2021; 13:e13131Hazwani TR, Al

Hassan Z, Al Zahrani A, Al Badawi A. http://www.ncbi.nlm.nih.gov/pubmed/? term=33564560

7. Differences in Immune Responses between Children and Adults with

COVID-19. Curr Med Sci 2021; 41:58-61Yuan Y, Wang QP, Sun D et al.

8. A guidance on diagnosis and management of hyperglycemia at COVID care

facilities in India. Diabetes Metab Syndr 2021; 15:407-413Gupta Y, Goyal A,

Kubihal S et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=33581594

9. Seroprevalence of antibodies against SARS-CoV-2 among health care workers

in a pediatric monographic hospital in Madrid (Spain). Enferm. Infecc. Microbiol.

Clin. 2021; Escribano Ceruelo E, Espinel Ruíz MA, Ortega López-Peláez M et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=33563481

10. Age-Related Changes in Clinical Presentation of Covid-19: the EPICOVID19

Web-Based Survey. Eur J Intern Med 2021; Trevisan C, Noale M, Prinelli F et al.

11. Collateral impact of COVID-19: why should children continue to suffer? Eur. J. Pediatr. 2021; Nagakumar P, Chadwick CL, Bush A, Gupta A.

12. Consequences of coronavirus disease-2019 (COVID-19) lockdown on

infection-related hospitalizations among the pediatric population in Denmark.

Eur. J. Pediatr. 2021; Polcwiartek LB, Polcwiartek C, Andersen MP et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=33555426

13. Development of Psychological Problems Among Adolescents During School

Closures Because of the COVID-19 Lockdown Phase in Italy: A

Cross-Sectional Survey. Front Pediatr 2020; 8:628072Esposito S, Giannitto N, Squarcia A

14. COVID-19 and Pediatric Lung Disease: A South African Tertiary Center

Experience. Front Pediatr 2020; 8:614076Gray DM, Davies MA, Githinji L et al.